Blood Coagul Fibrinolysis 2021 Jun 11. Epub 2021 Jun 11.
Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands Hemocentro de Belo Horizonte, Fundação HEMOMINAS, Belo Horizonte, Brazil Center for Clinical Transfusion Research, Sanquin, Leiden, The Netherlands.
Up to 35% of patients with hemophilia A and 5% with hemophilia B develop neutralizing antibodies which can inhibit the therapeutic activity of factor replacement (inhibitors). Despite the clinical relevance of antifactor VIII and IX neutralizing antibodies, there is still a major gap on the knowledge of risk factors for their development. Furthermore, most of the studies on risk factors for inhibitor development come from Caucasian and Afro-American populations. Read More